Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
Authors:
Open Access
- 17 November 2016
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 101 (6) , 745-753
Abstract
Extended‐release (XR) formulations enable less frequent dosing vs. conventional (e.g., immediate release (IR)) formulations. Regulatory registration of such formulations typically requires pharmacokinetic (PK) and clinical efficacy data. Here we illustrate a model‐informed, exposure–response (E‐R) approach to translate controlled trial data from one formulation to another without a phase III trial, using a tofacitinib case study. Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). E‐R analyses were conducted using validated clinical endpoints from phase II dose–response and nonclinical dose fractionation studies of the IR formulation. Consistent with the delay in clinical response dynamics relative to PK, average concentration was established as the relevant PK parameter for tofacitinib efficacy and supported pharmacodynamic similarity. These evaluations, alongside demonstrated equivalence in total systemic exposure between IR and XR formulations, provided the basis for the regulatory approval of tofacitinib XR once daily by the US Food and Drug Administration.Keywords
Funding Information
- Pfizer
This publication has 39 references indexed in Scilit:
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Population pharmacokinetic–pharmacodynamic–disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritisJournal of Pharmacokinetics and Pharmacodynamics, 2011
- Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products: Workshop Summary ReportThe AAPS Journal, 2010
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritisJournal of Inflammation, 2010
- Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced ArthritisThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis RatsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Comparison of four basic models of indirect pharmacodynamic responsesJournal of Pharmacokinetics and Biopharmaceutics, 1993